Oncolytic virus immunotherapy

oncolytic herpes simplex virus

Oncolytic herpes simplex virus (oHSV) is one of oncolytic viruses being studied in cancer therapeutic research and several oHSVs have been investigated in clinical trials. ith the increasing experience and knowledge of HSV system, Creative Biolabs commits to developing efficacious oncolytic herpes simplex virus and enabling wider applications in oncolytic virotherapy of cancers. https://www.creative-biolabs.com/oncolytic-virus/oncolytic-herpes-simplex-virus.htm

Oncolytic Virotherapy

Stella Evelyn

Oncolytic viruses (OVs) are therapeutically useful viruses which selectively infect and damage cancerous tissues without causing harm to normal tissues. Every virus has a specific cellular tropism that determines which tissues are preferentially infected, and what disease is caused. A number of naturally occurring viruses have a preferential, although non-exclusive, tropism for tumors and tumor cells. This probably has more to do with tumor biology than with virus biology as most tumors have evolved not only to avoid immune detection and destruction but also to resist apoptosis and translational suppression, which are the crucial responses used by normal cells to limit a virus infection. OVs can kill infected cancer cells in a number of different ways, ranging from direct virus-mediated cytotoxicity through various cytotoxic immune effector mechanisms.

Oncolytic virus basis

- Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells without harming normal cells, while simultaneously stimulating the immune system and creating antitumor immunity. - Early observations in the early 1900s found that some cancer patients experienced tumor regression after acquiring viral illnesses, which led researchers to hypothesize that genetically engineered viruses could be used to treat cancer. - Since the first OV entered clinical trials in 1996, various OVs have been successfully tested against many cancer types and numerous clinical trials are currently evaluating their efficacy and safety.

Oncolytic virus immunotherapy knowledge

ADEOYE OPEYEMI ADURAGBEMI

This document provides an overview of oncolytic viruses (OVs) as a potential cancer treatment. It discusses how OVs selectively target and kill cancer cells through direct lysis and stimulation of anti-tumor immunity. The mechanisms of OV action and various strategies for enhancing their efficacy are described, such as arming OVs with immunostimulatory genes or anti-angiogenic factors. Several OVs currently in clinical trials are highlighted, including T-VEC which was approved in 2015 for melanoma treatment. The document concludes that OVs show promise as a novel cancer immunotherapy but further research is still needed to address issues like viral resistance and toxicity.

ONCOLYTIC VIRUSES AS AN ANTICANCER AGENT........ _________

This document outlines oncolytic viruses as anticancer agents. It begins with an introduction discussing the rising rates of cancer deaths worldwide and in Nigeria. It then provides historical background on early human trials of viruses for cancer treatment in the 1940s-1970s. The document discusses the characteristics and mechanisms of action of ideal oncolytic viruses, including their ability to selectively infect and lyse cancer cells. It also examines the genomic organization of several oncolytic viruses like adenovirus, maraba virus, herpes simplex virus, vaccinia virus, and poliovirus. Finally, it reviews current genetic manipulations of oncolytic viruses in clinical trials and their targeting of tumors.

Presentacio¦ün nicole 2

Nicole Rivera

My first proposal, Everyone knows a person that have or had Cancer. We know that Cancer dosen't have a cure an yet the therapies for it, sometimes, do more harm to the person because the therapy do not choose what kind of cell is going to destroy. But if we can develop a new kind of treatment, a less agresive and more effective one, we will increase the survival chances and minimizes the secondary efects.

Carcinogens

Nasuhi Engin AYDIN

Potential value of bioinformatic analysis in regulatory process - OECD Bioinf...

human oncogenic viruses

SHUBHANGI2509

How can Whole Genome Sequencing information be used to address data requireme...

OMICS Group | International Science Conferences

This document discusses the potential use of whole genome sequencing data to address regulatory requirements for approval of microorganisms as active ingredients in plant protection products in the EU. It analyzes how genome sequencing could be used for species assignment, relationship to pathogens, distinction between Bacillus strains, production of metabolites, antibiotic resistance, genetic stability, risk assessment, and unequivocal identification of strains. While noting some potential benefits, it also describes limitations and problems with relying solely on genome sequencing data. It concludes that genome sequencing can be useful to exclude some issues but should not be a standard requirement, and that only reports on analyses—not the genome sequences themselves—should be included in dossiers.

Microbial sequencing

Dynah Perry

Until recently, the properties and compositions of the microbiota in the planet are still largely a black box. Next generation sequencing (NGS) has proven to be an invaluable tool for investigating diverse environmental and host-associated microbial communities, helping to generate enormous new data sets that can be mined for information on the composition and functional properties of vastly great numbers of microbial communities.

Molecular tumor testing overview

Andrew Begg

PBSS sf 10-28-2016 flyer

Vinita Gupta

This document announces a one-day symposium on biomarkers for immuno-oncology therapeutics to be held on October 28, 2016 in Foster City, CA. The symposium will introduce fundamentals, technologies, and applications of biomarkers in research, translational, and clinical development of immune-oncology treatments. Nine speakers from academia and biotech/pharma companies will present on topics such as maximizing anti-PD1 therapy, biomarker strategies for combination immunotherapy, biomarkers for novel checkpoint inhibitors, analysis of the tumor microenvironment, and prediction of tumor response to checkpoint inhibitors. The goal is for participants to learn the latest advancements and network with others in the field.

Clinical Microbiology & Microbial Genomics

KIYATEC-Advanced-CoCulture-LRes

☤ Bryce Chaney, MBA

KIYATEC has developed advanced 3D co-culture techniques to model tumor-immune cell interactions in vitro. Their models can maintain viability of primary breast cancer cultures for 64 days. They have created tri-, tetra-, and penta-culture models incorporating tumor cells and immune components to test immuno-oncology drugs. KIYATEC aims to develop the most clinically relevant personalized tumor models to assess immune therapies and targeted drugs.

US Perspective on use of bioinformatics in microbial pesticide regulation - O...

Overview of the commonly used sequencing platforms, bioinformatic search tool...

Oncolytic Virus Therapy Development - Creative Biolabs

Creative-Biolabs

Oncolytic virus basis

Oncolytic viruses (OVs) is a group of viruses that selectively replicate in and kill cancer cells, while leaving the normal tissue uninfected. OVs provide a diverse platform for immunotherapy; they act as in situ vaccines, and can be armed with immuno-modulatory transgenes or combined with other immunotherapies, such as immune-checkpoint inhibitor, engineered T cell, bi-specific antibody or chemotherapies. https://www.creative-biolabs.com/oncolytic-virus/oncolytic-virus-therapy-development.htm

Oncolyticvirustherapy 100128015237-phpapp01

Priyanka Gupta

This document provides an overview of oncolytic viral therapy as a treatment for cancer. It defines oncolytic viral therapy as using genetically modified viruses that selectively kill cancer cells. The document describes how viruses work, then explains the process of modifying a virus so that it is attracted to a tumor's proteins and will inject its DNA into cancer cells to replicate and kill them. It discusses some viruses like measles, herpes, and adenovirus that have shown success in clinical trials against various cancers. The benefits of oncolytic viral therapy are its targeted nature which leads to fewer side effects compared to other treatments.

Oncolytic virotheraphy

Abhishek Mishra

Oncolytic virotherapy uses viruses that selectively infect and kill cancer cells. Viruses are engineered to target features of cancer cells like overexpression of certain receptors. The viruses infect and replicate within cancer cells, causing them to lyse and release new virus particles to infect neighboring cancer cells. This repeats to destroy the tumor. Additionally, the viral infection stimulates anti-tumor immune responses. Oncolytic viruses show potential as a cancer therapy but challenges remain around the immune system clearing viruses too quickly and risks of new viral strains emerging.

oncolytic virus.pdf

RolaMaadarani1

Oncolytic viruses can be used to treat cancer by infecting and killing cancer cells. They have the potential advantages of direct killing, inducing anti-tumoral and anti-viral immunity, and eliciting innate and adaptive immune responses. However, their effects may vary between individuals and they can be cleared by the immune system. Oncolytic viruses work by hijacking the cancer cell's protein production, triggering "danger signals" and releasing viral progeny to infect neighboring cells, which stimulates anti-cancer immunity locally and systemically.

Introduction and Mechanism of Oncolytic Virus Therapy.pdf

With a better understanding of cancer biology and virology, oncolytic virus therapy is becoming a promising treatment modality for tumor targeting and offers unique opportunities for tumor therapy. Taking advantage of our OncoVirapy™ platform, Creative Biolabs can provide high-quality oncolytic virus-based therapy development. https://www.creative-biolabs.com/oncolytic-virus/introduction-and-mechanism-of-oncolytic-virus-therapy.htm

Oncolytic Herpes Simplex Virus.pdf

This document discusses oncolytic viruses, which are viruses that can selectively target and kill cancer cells. It covers the mechanisms of oncolytic viruses, factors to consider in their development like size and pathogenicity, and different families of oncolytic viruses. Specific oncolytic viruses discussed include herpes simplex virus, T-VEC, HF10, and vaccinia virus. The document also examines combination therapies using oncolytic viruses and biomarkers for assessing their delivery and activity in tumor immunotherapy.

What's hot

oncolytic virus immunotherapy

ADEOYE OPEYEMI ADURAGBEMI

Seminar-Oncolytic viruses

Ashwini Chaple

ONCOLYTIC VIRUSES AS AN ANTICANCER AGENT........ _________

Presentacio¦ün nicole 2

Nicole Rivera

Carcinogens

Nasuhi Engin AYDIN

Potential value of bioinformatic analysis in regulatory process - OECD Bioinf...

human oncogenic viruses

SHUBHANGI2509

How can Whole Genome Sequencing information be used to address data requireme...

OMICS Group | International Science Conferences

Microbial sequencing

Dynah Perry

Molecular tumor testing overview

Andrew Begg

PBSS sf 10-28-2016 flyer

Vinita Gupta

Clinical Microbiology & Microbial Genomics

KIYATEC-Advanced-CoCulture-LRes

☤ Bryce Chaney, MBA

US Perspective on use of bioinformatics in microbial pesticide regulation - O...

Overview of the commonly used sequencing platforms, bioinformatic search tool...

What's hot (15)

oncolytic virus immunotherapy

Seminar-Oncolytic viruses

ONCOLYTIC VIRUSES AS AN ANTICANCER AGENT........ _________

Presentacio¦ün nicole 2

Carcinogens

Potential value of bioinformatic analysis in regulatory process - OECD Bioinf...

human oncogenic viruses

How can Whole Genome Sequencing information be used to address data requireme...

Microbial sequencing

Molecular tumor testing overview

PBSS sf 10-28-2016 flyer

Clinical Microbiology & Microbial Genomics

KIYATEC-Advanced-CoCulture-LRes

US Perspective on use of bioinformatics in microbial pesticide regulation - O...

Overview of the commonly used sequencing platforms, bioinformatic search tool...

Similar to Oncolytic virus immunotherapy

Oncolytic Virus Therapy Development - Creative Biolabs

Creative-Biolabs

Oncolytic virus basis

Oncolyticvirustherapy 100128015237-phpapp01

Priyanka Gupta

Oncolytic virotheraphy

Abhishek Mishra

oncolytic virus.pdf

RolaMaadarani1

Introduction and Mechanism of Oncolytic Virus Therapy.pdf

Oncolytic Herpes Simplex Virus.pdf

Introduction to Oncolytic Viruses

The Development of Oncolytic Viruses.pdf

Bahauddin Zakariya University lahore

Global oncolytic virus therapy market & pipeline outlook 2022

Rajesh Sarma

“Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials.

Cancer Immunotherapy

Thi K. Tran-Nguyen, PhD

This document summarizes a presentation on molecular basis of disease and cancer immunotherapy. It outlines tumor-immune system interactions and different types of immunotherapy, including passive and active approaches. Passive non-specific immunotherapy includes immune checkpoint blockade drugs like Ipilimumab and Nivolumab. Active non-specific immunotherapy includes cytokine therapy and BCG vaccine used to treat non-muscular invasive bladder cancer. Passive specific immunotherapy uses antibodies against tumor antigens or CAR-T cells. Active specific immunotherapy includes tumor vaccines using tumor antigens administered through DNA, proteins, dendritic cells or autologous tumor extracts. Challenges to cancer immunotherapy include tumor resistance, requirements for strong immune responses, and high costs.

oncogenic viruses by dr rahul acharya.pptx

rahulacharya52

Viruses and Cancer: Introduction to Oncoviruses

Aparna Dubey

Virotherapy,as a key for cancer treatment

Shirisha Ratcha

Cancer is caused by unusual cell growth due to genetic mutations and can form benign or malignant tumors. Oncolytic viral therapy uses viruses that specifically infect and destroy cancer cells by exploiting differences between normal and cancer cells. Various strategies are used for tumor targeting including pro-apoptotic targeting using viral genes, transcriptional targeting by placing viral genes under tumor-specific promoters, and transductional targeting based on overexpression of receptors on cancer cells. Adenoviruses and reoviruses have been studied extensively as oncolytic viruses due to their ability to selectively replicate in and lyse cancer cells.

Group of Dna viruses and viral vectors

nida rehman

This document discusses DNA viruses and viral vectors. It begins by introducing viruses and their classification based on host, morphology, genome, and structures. It then describes the Baltimore classification system for viruses. Viral vectors are discussed as effective means of gene transfer that can be manipulated to express therapeutic genes. Several virus types being investigated for gene delivery are described, including retroviruses, adenoviruses, adeno-associated viruses, and herpes simplex viruses. Key properties of viral vectors like safety, toxicity, stability, and cell specificity are outlined. Specific types of viral vectors - retroviral, lentiviral, adenoviral, adeno-associated viral, and herpes simplex viral vectors - are then characterized.

Antibodies, vaccines, adjuvents

This document discusses antibodies, vaccines, and adjuvants. It provides information on monoclonal and polyclonal antibodies, how they are produced, and their applications. It also discusses vaccines, including how traditional vaccines are prepared and different vaccine categories. Specific topics covered include hepatitis B vaccines, the impact of genetic engineering on vaccines, peptide vaccines, vaccine vectors, AIDS vaccine development and challenges.

Antibody cancer therapy

sumiyah zari

The document discusses monoclonal antibodies, including their discovery, structure, functions, types, production, targets for cancer treatment, and mechanisms of action. It provides details on how monoclonal antibodies can directly kill tumor cells or induce immune-mediated killing through mechanisms like phagocytosis, complement activation, and antibody-dependent cell cytotoxicity. The document also examines immune checkpoint inhibitors, immunotoxins, bispecific antibodies, immunoliposomes, antibody fragments, and an animal model study on monoclonal antibody treatment for colorectal cancer.

Advances in Oncolytic Virotherapy - Creative Biolabs

Creative-Biolabs

Oncolytic virotherapy, an innovative approach leverages the natural ability of viruses to infect and kill tumor cells, offering a beacon of hope for patients battling cancer. Our journey through this domain uncovers the mechanisms of action of oncolytic viruses, explores representative examples, discusses strategic modifications and combinations with other therapies, addresses challenges, and reviews the clinical status of this cutting-edge treatment.

Cancer Gene therapy

Ahmad Hady

Gene therapy aims to alter the phenotype of diseased cells by introducing exogenous nucleic acids like DNA. It involves choosing a cellular target, effector mechanism, delivery method, and effector gene. For cancer, common targets are tumor cells themselves or normal cells like stem cells. Effector mechanisms include gene replacement, suicide genes, and RNA-directed strategies. Delivery can be viral, non-viral, or involve artificial virus-like particles. Effector genes, promoters, and suicide genes must be chosen to match the intended target and effect. Some gene therapy strategies have shown effectiveness in clinical trials for cancers like breast and prostate.

Carcinogenesis

NarmathaN2

This document discusses carcinogenesis, or the process by which normal cells are transformed into cancer cells. It covers the molecular mechanisms of cancer development, including genetic mutations caused by chemical carcinogens, radiation, viruses, and other factors. The key stages of cancer development are initiation, promotion, and progression. Cancer results from the accumulation of multiple genetic alterations that cause cells to proliferate uncontrollably and evade growth suppression mechanisms. Understanding carcinogenesis can help improve early detection and prevention of cancer.

Similar to Oncolytic virus immunotherapy (20)

Oncolytic Virus Therapy Development - Creative Biolabs

Oncolytic virus basis

Oncolyticvirustherapy 100128015237-phpapp01

Oncolytic virotheraphy

oncolytic virus.pdf

Introduction and Mechanism of Oncolytic Virus Therapy.pdf

Oncolytic Herpes Simplex Virus.pdf

Introduction to Oncolytic Viruses

The Development of Oncolytic Viruses.pdf

Global oncolytic virus therapy market & pipeline outlook 2022

Cancer Immunotherapy

oncogenic viruses by dr rahul acharya.pptx

Viruses and Cancer: Introduction to Oncoviruses

Virotherapy,as a key for cancer treatment

Group of Dna viruses and viral vectors

Antibodies, vaccines, adjuvents

Antibody cancer therapy

Advances in Oncolytic Virotherapy - Creative Biolabs

Cancer Gene therapy

Carcinogenesis

More from CandySwift_NY

SARS-CoV-2 Vaccines

The document discusses SARS-CoV-2 vaccines, describing how the virus infects cells, the immune response it provokes, and the different types of vaccines in development including virus, viral vector, nucleic acid and protein-based vaccines; it provides an overview of the vaccine development process and pipeline as well as the services offered by Creative Biolabs to support SARS-CoV-2 vaccine research and development.

Exosomes Biogenesis&Therapeutics

Genome Editing Introduction

Oncolytic Virus and Immunotherapy

Oncolytic viruses (OVs) provide a diverse platform for immunotherapy; they act as in situ vaccines, and can be armed with immuno-modulatory transgenes or combined with other immunotherapie. Taking advantage of the OncoVirapy™ platform, Creative Biolabs provides high-quality oncolytic virus therapy development services for clients globally. https://www.creative-biolabs.com/oncolytic-virus/oncolytic-virotherapy-development-for-combination-therapy-with-cancer-immunotherapy.htm

Introduction of SARS-CoV-2

SARS-CoV-2 was first identified in Wuhan, China in late 2019 and has since spread to over 200 countries. It belongs to the coronavirus family and causes the disease COVID-19. The virus enters cells through the ACE2 receptor and replicates its RNA and proteins before being released to infect other cells. Potential treatment strategies include using existing antiviral drugs, developing specific drugs that target the virus genome or proteins, and enhancing immune responses. Ongoing research focuses on antibody development, diagnostic assays, vaccines, and other medical countermeasures to treat and prevent the spread of SARS-CoV-2.

SARS-CoV-2 Introduction_Creative Biolabs

The severity and emergency of SARS-CoV-2 infection spurs an urgent need for antiviral drug and vaccine discovery. Creative Biolabs has spent considerable efforts to provide scientific support and comprehensive services to promote the success of this combat. Equipped with cutting-edge techniques and vast experience, Creative Biolabs is keeping up with current research hotspots and integrating all resources to guarantee high-quality services (including but not limiting to): Antiviral Drug Discovery, Vaccine Discovery, Evaluation Platforms, In Vitro Diagnostic (IVD) Immunoassays. https://sars-cov-2.creative-biolabs.com/novel-coronavirus-sars-cov2.htm

SARS-CoV-2 Introduction_Creative Biolabs

Complement Therapeutics_Creative Biolabs

Anti dengue-virus-antibody-products-and-services

Introduction to SARS-CoV-2-Creative Biolabs

An ongoing outbreak of a novel coronavirus (SARS-CoV-2) has raised global concerns. It is identified as the cause of pneumonia with unknown etiology. Since the early outbreak in Wuhan, China, it has subsequently spread to all provinces of China and many other countries. The urgent epidemic situation has spurred the development of antiviral drugs and vaccines. As a leading service provider in the field of biological research and drug discovery, Creative Biolabs provides fast & elaborate therapeutic antibody discovery, drug candidates screening and vaccine development services to help combat this outbreak. https://sars-cov-2.creative-biolabs.com/novel-coronavirus-sars-cov2.htm

Creative biolabs.cart nk cell-based-therapeutics

In addition to adoptive transfer, NK cells are also involved in molecular based therapies. Stimulatory cytokines, small molecule activators/inhibitors, monoclonal antibodies (mAbs) including bispecific antibodies (bsAbs), and antibody-drug conjugates (ADCs) are utilized to target inhibitory/activating receptors/ligands, tumor antigens, immuno-suppressive molecules, and the tumor icroenvironment, to improve the anti-tumor activity of NK cells. https://www.creative-biolabs.com/bsab/

Exosome applications